Diabetes
Conditions
Interventions
Observation group:Received treatment with the long-acting DPP4 enzyme inhibitor, saxagliptin, at a dose of 10 mg every two weeks (Q2W).
Experimental group:The experimental group was treated with 10mg of saxagliptin every two weeks (Q2W) in combination with an auxiliary decision support system. This auxiliary decision support system is
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age over 60 years old; 2. Newly diagnosed with type 2 diabetes within the past year; 3.Only received DPP-4 inhibitor daily preparations and/or metformin treatment within the 3 months prior to enrollment; 4.FPG < 15 mmol/L and HbA1c <= 10.5% within the 3 months prior to enrollment. 5. Able to understand the procedures and methods of this trial, willing to comply with the clinical research protocol to complete this trial, and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Participants who had experienced acute diabetic events within 6 months before enrollment; 2.Those with severe diseases (such as cancer, HIV, severe peripheral vascular disease, various immune system diseases, severe mental disorders or language barriers); 3. Those who had used other drugs that might affect glucose metabolism within 6 months before enrollment (such as systemic glucocorticoids, growth hormones, etc.); 4. Those who had experienced acute coronary syndrome, stroke or transient ischemic attack within 3 months before enrollment, or had uncontrolled hypertension (such as systolic blood pressure = 160mmHg, diastolic blood pressure = 90mmHg) before enrollment; 5.Those who were participating in other clinical trials; 6. Other situations deemed unsuitable for participation in this study by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of HbA1c from baseline; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time in range (TIR);Diabetes treatment satisfaction questionnaire;Time above target glucose range (TAR);Time below target range (TBR);Mean glucose level (MG);Coefficient of variation (CV) of blood glucose;Serious Adverse events;Hypoglycemic events; | — |
Countries
China
Contacts
Public ContactQi Pan
Beijing Hospital
Outcome results
None listed